Cantor Fitzgerald Initiates Milestone Pharmaceuticals Coverage with Overweight Rating and $3 Price Target

Cantor Fitzgerald has initiated coverage on Milestone Pharmaceuticals (NASDAQ:MIST) with an overweight rating and a price target of $3.00, signaling significant upside potential for the biotechnology company. The firm announced the rating on Wednesday, with analyst Olivia Brayer Saunders leading the coverage initiation. The stock currently trades at $1.08, representing a 46.5% decline…